How Much Weight Can You Lose With Orlistat?

Most people who take orlistat at the prescription dose and follow a reduced-calorie diet lose roughly 5 to 10 percent of their starting body weight within the first year, with about half of that loss attributable to the drug itself rather than diet alone. That puts orlistat solidly in the category of modest but real weight-loss assistance, not a dramatic transformation tool. How much you actually lose depends on your diet, how long you stick with the medication, and how your body responds to a drug that works in the gut rather than the brain.

How Orlistat Blocks Fat

Orlistat works by disabling the enzymes that break down dietary fat in your digestive tract. Without those enzymes doing their job, roughly a third of the fat you eat passes through your body undigested and unabsorbed.¹ The drug targets gastric and pancreatic lipases specifically, and it does so locally in the gut without entering the bloodstream in any meaningful amount.² This is why orlistat’s side-effect profile is almost entirely gastrointestinal rather than neurological or cardiovascular. It simply prevents your body from collecting a portion of the calories you ate as fat.

Because it only works on fat, orlistat does nothing about calories from carbohydrates, protein, or alcohol. If your diet is already low in fat, there is less for the drug to block, and your weight loss will be smaller. This is a key reason results vary so much from person to person.

What the Trials Actually Show

The clearest picture comes from large, placebo-controlled trials. In one of the landmark studies, patients on orlistat 120 mg three times daily plus a calorie-reduced diet lost about 10 percent of their body weight over the first year, compared with about 6 percent for those on diet and placebo alone. In absolute terms, the orlistat group lost around 10.3 kg while the placebo group lost 6.1 kg.³ So the drug itself was responsible for roughly an extra 4 kg of weight loss beyond what diet and behavior change achieved.

A large European trial found similar results, with the 120 mg orlistat group losing about 9.7 percent of their body weight in year one versus 6.6 percent for placebo.⁴ These numbers consistently tell the same story across trials: expect the drug to roughly double the gap between “diet alone” and “diet plus medication,” but don’t expect that gap to be enormous. The drug-attributable portion is typically in the range of 3 to 4 kg over a year.

What Happens After the First Year

Weight loss with orlistat tends to peak somewhere around six months to a year, after which the challenge shifts from losing weight to keeping it off. This is where orlistat shows a different kind of value. In a two-year trial, patients who continued orlistat during the second year regained substantially less weight than those switched to placebo. Patients switched from orlistat to placebo regained an average of 2.5 kg, while those who stayed on the drug regained about half that amount.⁵ The drug doesn’t prevent regain entirely, but it slows it down.

The longest major trial, called XENDOS, followed patients for four years. Those on orlistat lost an average of 5.8 kg over the full period, compared with 3.0 kg for placebo.⁶ That four-year number is lower than the one-year peaks because it includes the slow regain that happens over years two through four. This pattern of lose-then-regain is not unique to orlistat. It happens with nearly every weight-loss intervention, including surgery. Orlistat just makes the regain somewhat gentler while you continue taking it.

The Gastrointestinal Side Effects Are the Price of Admission

The fat that orlistat prevents your body from absorbing has to go somewhere, and that somewhere is your toilet. Oily or fatty stools, fecal urgency, and occasional oily spotting on underwear are the most common complaints. These side effects are not really “side” effects at all. They are the direct, predictable consequence of the drug doing exactly what it is designed to do.

How severe these symptoms get depends heavily on how much fat you eat. A high-fat meal while on orlistat can produce unpleasant and sometimes embarrassing gastrointestinal results. Some researchers have pointed out that this essentially builds dietary enforcement into the pill: patients who eat too much fat get punished with symptoms, which pushes them toward lower-fat meals and reinforces the dietary changes they need for long-term weight management.⁷ Whether you see that as a feature or a bug depends on your perspective, but it is one reason orlistat’s weight loss often holds up reasonably well in practice: the drug trains you to eat less fat or face the consequences.

In adolescent trials, the most frequently reported problems were the same: fecal urgency, incontinence, and fatty stools. These were generally rated as mild to moderate, but they are understandably a bigger deal for a teenager in a school setting.⁸

How It Works for Adolescents

Orlistat is one of the few weight-loss medications approved for use in adolescents aged 12 and older. The results in younger patients look different from those in adults, partly because teenagers are still growing. In a major pediatric trial, adolescents on orlistat didn’t lose large amounts of weight in absolute terms. Instead, their weight barely changed, increasing by about half a kilogram over a year, while placebo-treated teens gained more than 3 kg.⁹ In a growing adolescent, holding weight steady while getting taller is a meaningful outcome, because body mass index falls as height increases. In the same trial, BMI decreased by about half a point with orlistat but increased by about a third of a point with placebo.⁸

If you are a parent looking at those numbers and thinking they seem underwhelming, the honest answer is that they are modest. Orlistat in adolescents is more about damage control and building better habits than about dramatic weight loss.

Benefits Beyond the Scale

Some of the most interesting findings about orlistat have nothing to do with what the scale reads. Because the drug reduces fat and cholesterol absorption in the gut, it produces metabolic improvements that are partially independent of the weight loss itself.

In people with type 2 diabetes, orlistat lowered fasting blood sugar and HbA1c (the standard measure of blood sugar control over time) significantly more than placebo. What stood out was that even among patients who lost very little weight, orlistat still improved blood sugar control. The researchers concluded the glycemic benefit was at least partly independent of how much weight was lost.¹⁰ This likely has to do with the drug directly reducing fat absorption in the gut, which changes how the body handles glucose after meals.

In the four-year XENDOS trial, orlistat also reduced the incidence of new type 2 diabetes in people who were at high risk. That finding helped establish orlistat as not just a weight-loss drug but a potential tool for diabetes prevention.¹¹

Cholesterol also responds to orlistat. A meta-analysis pooling data from 33 randomized trials found that orlistat reduced total cholesterol and LDL cholesterol to a modest but statistically meaningful degree. The LDL reduction was larger in patients who lost more weight and in those on shorter treatment courses.¹² Part of this cholesterol-lowering appears to come from orlistat directly blocking the absorption of dietary cholesterol in the gut, separate from any weight-loss effect.¹³

Blood pressure sees a small nudge downward as well. A meta-analysis of 27 trials found that orlistat users had a modest drop in both systolic and diastolic blood pressure, and the effect grew with longer treatment duration.¹⁴ In patients who already had high blood pressure, the reductions were larger. One trial found orlistat brought systolic pressure down by about 9.4 mmHg compared with 4.6 mmHg for placebo in people with isolated systolic hypertension.¹⁵

Vitamin Absorption and What to Supplement

Because orlistat prevents fat absorption, it also interferes with the absorption of fat-soluble vitamins: A, D, E, and K. This is predictable biology. These vitamins dissolve in fat to get into your bloodstream, so if fat is passing through unabsorbed, it carries some of those vitamins with it.

A multivitamin is recommended for anyone taking orlistat, but even with supplementation, vitamin D levels can fall. In a study of adolescents taking orlistat along with a daily multivitamin, vitamin D levels dropped significantly after just one month of treatment. Vitamin E absorption was also reduced, while vitamins A and K held up better in the short term.¹⁶ The practical takeaway is to take a multivitamin at least two hours before or after your orlistat dose, and to have your doctor check vitamin D levels periodically, especially if you are already at risk for deficiency.

Rare but Serious Risks

Orlistat’s safety profile is generally considered mild because its effects are mostly confined to the gut. But there are two uncommon concerns worth knowing about.

The first is kidney damage from oxalate. When orlistat blocks fat absorption, more oxalate (a compound found in many foods) becomes available for absorption in the colon. In susceptible people, that extra oxalate can end up in the kidneys and form crystals, leading to a condition called oxalate nephropathy. Case reports describe patients developing kidney failure that developed insidiously while they were taking orlistat.¹⁷ One documented case linked the onset of acute kidney injury to an increase in orlistat dose, with urine analysis revealing abundant calcium oxalate crystals.¹⁸ This is rare, but it is worth flagging for anyone with pre-existing kidney issues or a history of kidney stones.

The second concern is liver injury. Reports of elevated liver enzymes and, in rare cases, severe liver damage have appeared in post-marketing surveillance. A large UK study of nearly 100,000 orlistat users found that the vast majority of liver-related events were elevated lab values or jaundice, not severe liver failure. There was a single case of hepatitis and no cases of liver failure or necrosis in that cohort.¹⁹ At the same time, scattered case reports of severe liver injury do exist, with some patients developing damage within weeks of starting the drug.²⁰ The absolute risk appears very low, but if you develop symptoms like yellowing skin, dark urine, or abdominal pain, stop the drug and contact your doctor.

Drug Interactions to Watch

Because orlistat alters fat absorption, it can interfere with the absorption of certain medications that dissolve in fat. The most clinically significant interaction is with cyclosporine, an immunosuppressant used after organ transplants and in autoimmune conditions. A documented case involved a patient whose previously well-controlled autoimmune disease relapsed shortly after starting orlistat, because cyclosporine levels dropped below therapeutic range. The condition stabilized once orlistat was stopped.²¹ Thyroid hormone medications, certain anticoagulants, and some anti-seizure drugs can also be affected. If you take any medication that depends on fat for absorption, your prescriber needs to know you are on orlistat.

How Orlistat Compares to Newer Medications

The weight-loss medication landscape has changed dramatically in recent years. GLP-1 receptor agonists like semaglutide (Wegovy) and liraglutide (Saxenda) produce substantially larger average weight losses than orlistat, often in the range of 10 to 15 percent of body weight from the drug itself. Orlistat’s drug-attributable loss of roughly 3 to 4 percent looks small by comparison.

That said, orlistat occupies a different niche. It is available over the counter in many countries at a lower dose (60 mg, sold as Alli in the United States), it does not require injections, and it has decades of safety data behind it. It also costs far less than the newer injectable medications, which can run over a thousand dollars per month without insurance. For someone who cannot access or tolerate the newer drugs, orlistat remains a reasonable if more modest option.²²

Real-World Adherence and How People Actually Use It

Clinical trial results represent what happens under controlled conditions with regular follow-up. In real life, adherence to orlistat is often lower. In one study tracking patients prescribed orlistat over six months, the majority lost some weight and improved their diet, but many had also stopped taking the drug before the six months were up. A sizable portion reported using orlistat flexibly rather than consistently, taking it with some meals and skipping it with others, essentially treating it as a lifestyle tool rather than a strict daily medication.⁷

This flexible use pattern may partly explain why real-world weight loss with orlistat tends to be lower than what trials report. Whether that flexible approach is actually a problem is debatable. If someone uses orlistat intermittently and still loses a few kilograms they would not have otherwise, the drug has done something useful, even if it is less than the clinical trial numbers promised. The gastrointestinal side effects, while unpleasant, may also serve as a self-selecting mechanism: people who find them intolerable stop the drug early, while those who adjust their fat intake to minimize symptoms often end up with better eating habits regardless of whether they continue the medication.

Access patterns also vary by insurance type. Research has shown that patients on Medicaid and traditional Medicare are less likely to fill an orlistat prescription compared with those on commercial insurance, which adds a practical barrier for some of the populations who could benefit most from even modest weight loss.²³

The Paradox of Orlistat and Fatty Liver Disease

One of the more interesting corners of orlistat research involves its relationship with the liver. As mentioned, rare cases of liver injury have been reported. But in something of a paradox, orlistat has also shown promise in treating non-alcoholic fatty liver disease, the condition where excess fat accumulates in the liver and drives inflammation. Research has found that orlistat can lower liver enzymes associated with fat-related liver damage and reduce liver fat content, likely because reducing dietary fat absorption also reduces the flood of fatty acids reaching the liver.²⁰ The same drug can, in rare individuals, harm the liver through what appears to be a hypersensitivity reaction, while in the broader population it may actually help protect the liver by reducing its fat burden. Researchers have not fully reconciled these two observations, which is part of why the science around orlistat and liver health remains unsettled.